navenibart
navenibart: sourced relationships with 1 company · 2 clinical trials tracked.
navenibart evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could navenibart → ATXS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| Astria Therapeutics, Inc. (ATXS) | Phase 3 |
| Astria Therapeutics, Inc. (ATXS) | Phase 2 |
Clinical Trial Registry Records (2)
A Phase 3 Trial to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants With Hereditary Angioedema - ORBIT-EXPANSE
Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants With Hereditary Angioedema (HAE)
Primary endpoint: Number of time-normalized investigator-confirmed HAE attacks during the 6-month Treatment Period.
Frequently asked questions
Which companies have sourced relationships with navenibart?
navenibart has dated SEC/FDA relationship records for Astria Therapeutics, Inc..
How many clinical trials involve navenibart?
BioSniper tracks 2 clinical trials involving navenibart.